Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 20, 2018 | June 22, 2018 |
| CareDx, Inc.CDNA · Entity 4344 | Director | June 12, 2026 | June 16, 2026 |
| FIVE PRIME THERAPEUTICS, INC.FPRX · Entity 16595 | Director | May 10, 2017 | May 12, 2017 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director | May 27, 2026 | May 29, 2026 |
| Progyny, Inc.PGNY · Entity 4521 | Director | May 23, 2024 | May 29, 2024 |
| Roka BioScience, Inc.ROKA · Entity 172682 | Director | June 28, 2017 | June 30, 2017 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | November 15, 2018 | November 19, 2018 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Director | August 06, 2024 | August 08, 2024 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | October 19, 2020 | October 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.09 · Expires 2028-06-20 | Direct | 30,000 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2: Vests 1/12th per month over twelve months beginning July 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
F2: Vests 1/12th per month over twelve months beginning July 20, 2018.
CareDx, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 165,060 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 9,795 · Balance 165,060 F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date.
FIVE PRIME THERAPEUTICS, INC.
Report date May 10, 2017 · Filed May 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80 · Expires 2027-05-09 | Direct | 10,000 |
Reported balance
After 2017-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-10 · Grant · Acquired 10,000 · Balance 10,000 F1: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date.
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,653 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 216,653 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Kyverna Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,727 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 5,093 · Balance 21,727 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2036-05-27 | Direct | 20,582 |
Reported balance
After 2026-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-27 · Grant · Acquired 20,582 · Balance 20,582 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,523,924 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,523,924 F3: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F3: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any.
Progyny, Inc.
Report date May 23, 2024 · Filed May 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,693 |
Reported balance
After 2024-05-23 transaction · row 1
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 6,176 · Balance 22,693 F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.15 · Expires 2034-05-22 | Direct | 25,070 |
Reported balance
After 2024-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-23 · Grant · Acquired 25,070 · Balance 25,070 F2: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
F2: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
Roka BioScience, Inc.
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2027-06-27 | Direct | 3,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 3,000 · Balance 3,000 |
TANDEM DIABETES CARE INC
Report date November 15, 2018 · Filed November 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.12 | Direct | 25,000 |
Reported balance
After 2018-11-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-15 · Grant · Acquired 25,000 · Balance 25,000 F1: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2: All shares subject to the option will vest in equal monthly installments over 12 months. F3: The expiration date for these options is 10 years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.
F2: All shares subject to the option will vest in equal monthly installments over 12 months.
F3: The expiration date for these options is 10 years from the date of grant.
UroGen Pharma Ltd.
Report date August 06, 2024 · Filed August 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right ot buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.16 · Expires 2034-08-06 | Direct | 10,000 |
Reported balance
After 2024-08-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-06 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
VERACYTE, INC.
Report date October 19, 2020 · Filed October 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2020-10-19 transaction · row 1
1 source rowRow 1 · 2020-10-19 · Exercise / conversion · Acquired 10,000 · Balance 10,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2020-10-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-19 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-08 · Disposition to issuer · Disposed 68,165 · Balance 955 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,874,586 and 30,703 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. Row 2 · 2019-11-08 · Disposition to issuer · Disposed 955 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Common StockSEC Table I · non-derivative | IndirectBy the Jane K Cohen Trust | 0 |
Reported balance
After 2019-11-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-11-08 · Disposition to issuer · Disposed 6,068 · Balance 0 F3: Disposed of in connection with the Merger pursuant to the Merger Agreement, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $166,888 and 2,733 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.87 · Expires 2023-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Disposition to issuer · Disposed 8,250 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $105,114 and 1,721 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.04 · Expires 2023-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Disposition to issuer · Disposed 1,515 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.53 · Expires 2027-06-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.72 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.41 · Expires 2029-06-14 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-08 · Disposition to issuer · Disposed 6,583 · Balance 0 F9: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,874,586 and 30,703 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F3: Disposed of in connection with the Merger pursuant to the Merger Agreement, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $166,888 and 2,733 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $105,114 and 1,721 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F9: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2017 Filed Jun 7, 2017 21:15 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001384101-17-000034 · wf-form4_149687011280183.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 19:59 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,941 | $5.15 | $9,996.15 |
DisclosureSEC source: 0001127602-17-020290 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,410 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019327 · form4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 19, 2017 Filed May 23, 2017 20:16 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 8,250 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-17-034764 · doc4.xml · derivative · entry 4 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2020-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2017 Filed May 23, 2017 20:16 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 8,250 | $29.54 | $243,744.60 |
DisclosureSEC source: 0001209191-17-034764 · doc4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,895 F1 · price: Represents weighted average sale price. Actual sale prices ranged from $29.35 to $29.80. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Read SEC document |
| May 19, 2017 Filed May 23, 2017 20:16 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 8,250 | $14.37 | $118,552.50 |
DisclosureSEC source: 0001209191-17-034764 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 22, 2017 18:59 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 8,250 | $0.00 Strike: $17.59 | $0.00 |
DisclosureSEC source: 0001209191-17-034483 · doc4.xml · derivative · entry 6 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2019-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 22, 2017 18:59 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionDirector Stock Options (right to buy) · Derivative | 8,250 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001209191-17-034483 · doc4.xml · derivative · entry 5 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2018-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 22, 2017 18:59 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 16,500 | $29.88 | $493,039.80 |
DisclosureSEC source: 0001209191-17-034483 · doc4.xml · nonDerivative · entry 3 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,895 F1 · price: Represents weighted average sale price. Actual sale prices ranged from $29.79 to $29.95. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Read SEC document |
| May 18, 2017 Filed May 22, 2017 18:59 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 8,250 | $17.59 | $145,117.50 |
DisclosureSEC source: 0001209191-17-034483 · doc4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 22, 2017 18:59 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 8,250 | $18.50 | $152,625.00 |
DisclosureSEC source: 0001209191-17-034483 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2017 Filed May 18, 2017 19:52 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 8,250 | $0.00 Strike: $18.13 | $0.00 |
DisclosureSEC source: 0001209191-17-033742 · doc4.xml · derivative · entry 4 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2017-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2017 Filed May 18, 2017 19:52 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 8,250 | $30.68 | $253,101.75 |
DisclosureSEC source: 0001209191-17-033742 · doc4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,895 F1 · price: Represents weighted average sale price. Actual sale prices ranged from $30.55 to $31.05. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Read SEC document |
| May 16, 2017 Filed May 18, 2017 19:52 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 8,250 | $18.13 | $149,572.50 |
DisclosureSEC source: 0001209191-17-033742 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:20 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001209191-17-031937 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 17:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 317 | $31.49 | $9,982.33 |
DisclosureSEC source: 0001209191-17-025134 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,895 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 22:05 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 5,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-009331 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,901 F1 · shares: Represents an automatic, quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 20:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,602 | $6.24 | $9,996.48 |
DisclosureSEC source: 0001127602-17-009566 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,469 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 19:17 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 340 | $29.39 | $9,992.60 |
DisclosureSEC source: 0001209191-17-001499 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,578 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 00:47 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 3,391 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-000344 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,630 F1 · shares: Represents an automatic, quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 19:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,788 | $5.59 | $9,994.92 |
DisclosureSEC source: 0001127602-16-068905 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,867 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 01:02 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Options · Derivative | 17,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-16-150722 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 19:43 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 345 | $28.92 | $9,977.40 |
DisclosureSEC source: 0001209191-16-144721 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,238 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 23:46 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 2,643 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-031007 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,239 F1 · shares: Represents an automatic, quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 19:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 2,433 | $4.11 | $9,999.63 |
DisclosureSEC source: 0001127602-16-061901 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,079 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| June 17, 2015 Filed Jul 15, 2019 20:18 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 5,255 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0000899243-19-019606 · doc4a.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,255 Underlying: Common Stock · 5,255 shares Expires 2025-06-17 F1 · derivative.exercise_price: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. F1 · date: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. F1 · price: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. F1 · derivative.exercise_date: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 17, 2015 and 1/12th of the shares subject to the option shall vest monthly thereafter. F1 · derivative.expiration_date: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.